Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 8 art units • 13 examiners • 0 of 13 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Mirati Therapeutics Inc. manages an active portfolio with 11 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 11 distinct examiners, indicating a high degree of diversification in the individuals reviewing the company's innovations. Despite this wide range of examiners, the work is concentrated within 6 distinct art units. This suggests that while many different officials are involved, they are grouped within a relatively small number of specialized departments within the Biotechnology & Pharmaceuticals sector.
The prosecution landscape is notably decentralized, as the busiest examiner, SANCHEZ, JUSTIN CHRISTOPHER, is responsible for only 1 pending office action. This means that no single examiner has a dominant influence over the 11 pending office actions currently active. Practitioners must prepare for 11 different sets of examiner preferences across the 6 distinct art units. Such a spread requires a versatile strategy to maintain consistency across the Biotechnology & Pharmaceuticals filings, as the 11 distinct examiners may interpret prior art or procedural requirements differently.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §102 only | 2 (15%) |
| §112 only | 3 (23%) |
| Double-patenting + other | 3 (23%) |
| Multi-statute (no §101) | 4 (31%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 87.3% | +12.1% |
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| SCHMITT, MICHAEL J | 1 | 57.0% | +20.4% |
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| JARRELL, NOBLE E | 1 | 80.9% | +10.0% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 74.5% | +36.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19045764 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18694848 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | WILLIS, DOUGLAS M | — |
| 18572110 | Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors | INAM, SAHAR | — |
| 18543421 | COMBINATION THERAPIES | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286961 | KRAS G12C INHIBITORS | SEITZ, ANTHONY JOSEPH | 49d overdue |
| 18875584 | PRODRUGS OF PAN-KRAS INHIBITORS | WELLS, LAUREN QUINLAN | — |
| 18694921 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | SCHMITT, MICHAEL J | — |
| 18688995 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | KIFLE, BRUCK | — |
| 18571051 | SOS1 INHIBITORS | HEASLEY, MEGHAN CHRISTINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19045764 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18878118 | SALTS OF SOS1 INHIBITORS | KENYON, JOHN S | — |
| 18875584 | PRODRUGS OF PAN-KRAS INHIBITORS | WELLS, LAUREN QUINLAN | — |
| 18658666 | Substituted Quinoxalines | LEE, CHIHYI NMN | — |
| 18694848 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | WILLIS, DOUGLAS M | — |
| 18694921 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | SCHMITT, MICHAEL J | — |
| 18688995 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | KIFLE, BRUCK | — |
| 18543421 | COMBINATION THERAPIES | JARRELL, NOBLE E | — |
| Art Unit | Apps |
|---|---|
| 1629 | 4 |
| 1622 | 2 |
| 1624 | 2 |
| 1625 | 1 |
| 1628 | 1 |
| 1699 | 1 |
| 1626 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19045764 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112DP | Non-Final OA | — | Pending | Feb 05, 2025 |
| 18878118 | SALTS OF SOS1 INHIBITORS | KENYON, JOHN S | 1629 | §112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18875584 | PRODRUGS OF PAN-KRAS INHIBITORS | WELLS, LAUREN QUINLAN | 1625 | §102§103§112 | Non-Final OA | — | Pending | Dec 16, 2024 |
| 18658666 | Substituted Quinoxalines | LEE, CHIHYI NMN | 1628 | §102§103§112DP | Non-Final OA | — | Pending | May 08, 2024 |
| 18694848 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18694921 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | SCHMITT, MICHAEL J | 1629 | §103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18688995 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | KIFLE, BRUCK | 1624 | §102§103§112 | Non-Final OA | — | Pending | Mar 04, 2024 |
| 18572110 | Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors | INAM, SAHAR | 1622 | §102 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18543421 | COMBINATION THERAPIES | JARRELL, NOBLE E | 1699 | §103§112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18571051 | SOS1 INHIBITORS | HEASLEY, MEGHAN CHRISTINE | 1626 | §102§103§112Other | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18286961 | KRAS G12C INHIBITORS | SEITZ, ANTHONY JOSEPH | 1629 | §101DP | Final Rejection | 49d overdue | Pending | Oct 13, 2023 |
| 18549864 | MTA-Cooperative PRMT5 Inhibitors | NOTTINGHAM, KYLE GREGORY | 1621 | §112Other | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18229662 | QUINAZOLINE PAN-KRas INHIBITORS | TOWNSLEY, SARA ELIZABETH | 1629 | §102 | Non-Final OA | 9d | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMirati Therapeutics Inc. has 13 pending office actions as of October 2026, spread across 8 art units and 13 examiners.
Justin Christopher Sanchez has the most, with 1 of Mirati Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
